Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension

American Journal of Physiology - Renal Physiology

Volumn 291, Issue 3, 2006, Pages

  Opay, Allison L ^a   Mouton, Cynthia R ^a   Mullins, John J ^b   Mitchell, Kenneth D ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Glomerular filtration rate; Kidney; Meclofenamate; Nimesulide; Renal hemodynamics; Renal plasma flow; Renin angiotensin system

Indexed keywords

3 INDOLEMETHANOL; ANGIOTENSIN II; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450 1A1; HYDROCARBON; MECLOFENAMIC ACID; NIMESULIDE; PENTOBARBITAL; PROSTANOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFECT; DRUG INHIBITION; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; MALE; MALIGNANT HYPERTENSION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENIC ANIMAL;

EID: 33748436682     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00032.2006     Document Type: Article

References (61)

1. 2 receptors in control of murine renal hemodynamics. Am J Physiol Heart Circ Physiol 280: H327-H333, 2001.
2. Baber SR, Champion HC, Bivalacqua TJ, Hyman AL, and Kadowitz PJ. Role of cyclooxygenase-2 in the generation of vasoactive prostanoids in the rat pulmonary and systemic vascular beds. Circulation 108: 896-901, 2003.
3. Baber SR, Hyman AL, and Kadowitz PJ. Role of COX-1 and -2 in prostanoid generation and modulation of angiotensin II responses. Am J Physiol Heart Circ Physiol 285: H2399-H2410, 2003.
4. Baylis C and Brenner BM. Modulation by prostaglandin synthesis inhibitors of the action of exogenous angiotensin II on glomerular ultrafiltration in the rat. Circ Res 43: 889-898, 1978.
5. Blantz RC, Konnen KS, and Tucker BJ. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 57: 419-434, 1976.
6. Breyer MD, Zhang Y, Guan YF, Hao CM, Hebert RL, and Breyer RM. Regulation of renal function by prostaglandin E receptors. Kidney Int Suppl 67: S88-S94, 1998.
7. Campbell SJ, Carlotti F, Hall PA, Clark AJ, and Wolf CR. Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J Cell Sci 109: 2619-2625, 1996.
8. Capdevila JH and Falck JR. The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem Biophys Res Commun 285: 571-576, 2001.
9. Carmines PK, Morrison TK, and Navar LG. Angiotensin II effects on microvascular diameters of in vitro blood-perfused juxtamedullary nephrons. Am J Physiol Renal Fluid Electrolyte Physiol 251: F610-F618, 1986.
10. Caughey GE, Cleland LG, Penglis PS, Gamble JR, and James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective upregulation of prostacyclin synthesis by COX-2. J Immunol 167: 2831-2838, 2001.
11. Cheng HF and Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension 43: 525-530, 2004.
12. Ermert L, Ermert M, Goppelt-Struebe M, Walmrath D, Grimminger F, Steudel W, Ghofrani HA, Homberger C, Duncker H, and Seeger W. Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs. Am J Respir Cell Mol Biol 18: 479-488, 1998.
13. Ferguson S, Hebert RL, and Laneuville O. NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line. J Am Soc Nephrol 10: 2261-2271, 1999.
14. Forrester LM, Henderson CJ, Glancey MJ, Back DJ, Park BK, Ball SE, Kitteringham NR, McLaren AW, Miles JS, Skett P, and Wolf CR. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 281: 359-368, 1992.
15. Gelboin HV. Benzo[α]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol Rev 60: 1107-1166, 1980.
16. Harris RC and Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 281: F1-F11, 2001.
17. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, and Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94: 2504-2510, 1994.
18. Hartner A, Cordasic N, Goppelt-Struebe M, Veelken R, and Hilgers KF. Role of macula densa cyclooxygenase-2 in renovascular hypertension. Am J Physiol Renal Physiol 284: F498-F502, 2003.
19. Hawkey CJ. COX-2 inhibitors. Lancet 353: 307-314, 1999.
20. Hetu PO and Riendeau D. Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain. Biochem J 391: 561-566, 2005.
21. Ichihara A, Imig JD, and Navar LG. Cyclooxygenase-2 modulates afferent arteriolar responses to increases in pressure. Hypertension 34: 843-847, 1999.
22. Jaimes EA, Tian RX, Pearse D, and Raij L. Upregulation of glomerular COX-2 by angiotensin II: role of reactive oxygen species. Kidney Int 68: 2143-2153, 2005.
23. Jellinck PH, Forkert PG, Riddick DS, Okey AB, Michnovicz JJ, and Bradlow HL. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol 45: 1129-1136, 1993.
24. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, McGrath I, Kotelevtsev Y, and Mullins JJ. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem 276: 36727-36733, 2001.
25. Kantachuvesiri S, Haley CS, Fleming S, Kurian K, Whitworth CE, Wenham P, Kotelevtsev Y, and Mullins JJ. Genetic mapping of modifier loci affecting malignant hypertension in TGRmRen2 rats. Kidney Int 56: 414-420, 1999.
26. Kawada N, Dennehy K, Solis G, Modlinger P, Hamel R, Kawada JT, Aslam S, Moriyama T, Imai E, Welch WJ, and Wilcox CS. TP receptors regulate renal hemodynamics during angiotensin II slow pressor response. Am J Physiol Renal Physiol 287: F753-F759, 2004.
27. Lin L and Nasjletti A. Prostanoid-mediated vascular contraction in normotensive and hypertensive rats. Eur J Pharmacol 220: 49-53, 1992.
28. Lin L and Nasjletti A. Role of endothelium-derived prostanoid in angiotensin-induced vasoconstriction. Hypertension 18: 158-164, 1991.
29. Li Volti G, Seta F, Schwartzman ML, Nasjletti A, and Abraham NG. Heme oxygenase attenuates angiotensin II-mediated increase in cyclooxgenase-2 activity in human femoral endothelial cells. Hypertension 41: 715-719, 2003.
30. Loub WD, Wattenberg LW, and Davis DW. Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J Natl Cancer Inst 54: 985-988, 1975.
31. Luft FC, Wilcox CS, Unger T, Kühn R, Demmert G, Rohmeiss P, Ganten D, and Sterzel RB. Angiotensin-induced hypertension in the rat. Sympathetic nerve activity and prostaglandins. Hypertension 14: 396-403, 1989.
32. Mais DE, Saussy DL Jr, Chaikhouni A, Kochel PJ, Knapp DR, Hamanaka N, and Halushka PV. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. J Pharmacol Exp Ther 233: 418-424, 1985.
33. Mistry M and Nasjletti A. Role of pressor prostanoids in rats with angiotensin II-salt-induced hypertension. Hypertension 11: 758-762, 1988.
34. Mitchell KD and Mullins JJ. ANG II dependence of tubuloglomerular feedback responsiveness in hypertensive ren-2 transgenic rats. Am J Physiol Renal Fluid Electrolyte Physiol 268: F821-F828, 1995.
35. Mitchell KD and Mullins JJ. Enhanced tubuloglomerular feedback in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 289: F1210-F1216, 2005.
36. Mitchell KD and Navar LG. Enhanced tubuloglomerular feedback during peritubular capillary infusions of angiotensins I and II. Am J Physiol Renal Fluid Electrolyte Physiol 255: F383-F390, 1988.
37. Mitchell KD and Navar LG. Intrarenal actions of angiotensin II in the pathogenesis of experimental hypertension. In: Hypertension: Pathophysiology, Diagnosis, and Maintenance (2nd ed.), edited by Laragh JH and Brenner BM. New York: Raven, 1995, p. 1437-1450.
38. Mitchell KD and Navar LG. Modulation of tubuloglomerular feedback responsiveness by extracellular ATP. Am J Physiol Renal Fluid Electrolyte Physiol 264: F458-F466, 1993.
39. Narumiya S, Sugimoto Y, and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 79: 1193-1226, 1999.
40. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, and Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev 76: 425-536, 1996.
41. Needleman P, Turk J, Jakschik BA, Morrison AR, and Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem 55: 69-102, 1986.
42. Ohnaka K, Numaguchi K, Yamakawa T, and Inagami T. Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension 35: 68-75, 2000.
43. Pagano PJ, Lin L, Sessa WC, and Nasjletti A. Arachidonic acid elicits endothelium-dependent release from the rabbit aorta of a constrictor prostanoid resembling prostaglandin endoperoxidases. Circ Res 69: 396-405, 1991.
44. Patterson ME, Mouton CR, Mullins JJ, and Mitchell KD. Interactive effects of superoxide anion and nitric oxide on blood pressure and renal hemodynamics in transgenic rats with malignant hypertension. Am J Physiol Renal Physiol 289: F754-F759, 2005.
45. Pelkonen O and Nebert DW. Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. Pharmacol Rev 34: 189-222, 1982.
46. 2 actions in the microcirculation of rat kidney. Am J Physiol Renal Physiol 279: F755-F764, 2000.
47. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, and Breyer MD. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 110: 61-69, 2002.
48. Randriamboavonjy V, Busse R, and Fleming I. 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase. Hypertension 41: 801-806, 2003.
49. Rodriguez F, Llinás MT, González JD, Rivera J, and Salazar FJ. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension 36: 276-281, 2000.
50. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131-185, 2002.
51. Samuelsson B, Goldyne M, Granstrom E, Hamberg M, Hammarstrom S, and Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem 47: 997-1029, 1978.
52. Schlondorff D and Ardaillou R. Prostaglandins and other arachidonic acid metabolites in the kidney. Kidney Int 29: 108-119, 1986.
53. Schuijt MP, de Vries R, Saxena PR, and Jan Danser AH. Prostanoids, but not nitric oxide, counterregulate angiotensin II mediated vasoconstriction in vivo. Eur J Pharmacol 428: 331-336, 2001.
54. Shah AA, Murray FE, and Fitzgerald DJ. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. Rheumatology 38, Suppl 1: 19-23, 1999.
55. Shah AA, Thjodleifsson B, Murray FE, Kay E, Barry M, Sigthorsson G, Gudjonsson H, Oddsson E, Price AB, Fitzgerald DJ, and Bjarnason I. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 48: 339-346, 2001.
56. Smith JD, Wong E, and Ginsberg M. Cytochrome P450 1A1 promoter as a genetic switch for the regulatable and physiological expression of a plasma protein in transgenic mice. Proc Natl Acad Sci USA 92: 11926-11930, 1995.
57. 2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 107: 325-331, 2001.
58. Toda N and Miyazaki M. Angiotensin-induced relaxation in isolated dog renal and cerebral arteries. Am J Physiol Heart Circ Physiol 240: H247-H254, 1981.
59. Vane JR, Bakhle YS, and Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120, 1998.
60. Whitworth CE, Fleming S, Cumming AD, Morton JJ, Burns NJ, Williams BC, and Mullins JJ. Spontaneous development of malignant phase hypertension in transgenic Ren-2 rats. Kidney Int 46: 1528-1532, 1994.
61. Whitworth CE, Fleming S, Kotelevtsev Y, Manson L, Brooker GA, Cumming AD, and Mullins JJ. A genetic model of malignant phase hypertension in rats. Kidney Int 47: 529-535, 1995.